HSPG2 and melanoma: In this study, based on the integrated ICI-treated 631 melanoma and 109 NSCLC samples, we observed that HSPG2 mutations were predictive of a favorable ICI treatment outcome, which provides evidence for customizing immunotherapeutic strategies.